Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment
Abstract
Polyamines having the formula: or a salt thereof with a pharmaceutically acceptable acid wherein: R 1 -R 6 may be the same or different and are alkyl, aryl, aryl alkyl, cycloalkyl, optionally having an alkyl chain interrupted by at least one etheric oxygen atom, or hydrogen; N 1 , N 2 , N 3 and N 4 are nitrogen atoms capable of protonation at physiological pH's; a and b may be the same or different and are integers from 1 to 4; A, B and C may be the same or different and are bridging groups which effectively maintain the distance between the nitrogen atoms such that the polyamines: (i) are capable of uptake by a target cell upon administration thereof to a human or non-human animal; and (ii) upon uptake by the target cell, competitively bind via an electrostatic interaction between the positively charged nitrogen atoms to substantially the same biological counter-anions as the intracellular natural polyamines in the target cell; the polyamines, upon binding to the biological counter-anion in the cell, function in a manner biologically different than the intracellular polyamines, the polyamines not occurring in nature; as well as pharmaceutical compositions embodying the polyamines and methods of treating patients requiring anti-neoplastic therapy.
Claims
exact text as granted — not AI-modifiedI claim:
1 . A polyamine having the formula:
or a salt thereof with a pharmaceutically acceptable acid wherein:
R 1 -R 6 may be the same or different and are alkyl, aryl, aryl alkyl, cycloalkyl, optionally having an alkyl chains interrupted by at least one etheric oxygen atom, or hydrogen
N 1 , N 2 , N 3 and N 4 are nitrogen atoms capable of protonation at physiological pH's ;
a and b may be the same or different and are integers from 1 to 4;
A, B and C may be the same or different and are bridging groups which effectively maintain the distance between said nitrogen atoms such that said polyamine:
(i) is capable of uptake by a target cell upon administration of said polyamine to a human or non-human animal; and
(ii) upon uptake by said target cell, competitively binds via an electrostatic interaction between the positively charged nitrogen atoms to substantially the same biological counter-anions as the intra-cellular natural polyamines in the target cell;
said polyamine, upon binding to said biological counter-anion in the cell, functions in a manner biologically different than said intracellular polyamines, said polyamine not occurring in nature.
2 . A polyamine of claim 1 , upon binding to said biological counter-anion in said cell, exerting an anti-neoplastic function.
3 . A polyamine of claim 1 wherein said bridging groups A, B and C may be the same or different and are alkylene, branched alkylene, cycloalkylene, arylalkylene or a heterocyclic bridging group wherein one of said N 1 , N 2 , N 3 or N 4 atoms is incorporated in the ring as the hetero atom.
4 . A pharmaceutical composition comprising an anti-neoplastic effective amount of a polyamine of claim 1 or a salt thereof with a pharmaceutically acceptable acid and a pharmaceutically acceptable carrier therefor.
5 . A method of treating a human or non-human animal in need thereof comprising administering thereto an anti-neoplastic effective amount of a polyamine of claim 1 or a salt thereof with a pharmaceutically acceptable acid.
6 . A polyamine of claim 1 having the formula:
7 . A polyamine of claim 1 having the formula:
8 . A polyamine of claim 1 having the formula:Join the waitlist — get patent alerts
Track US2002143068A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.